Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KL271
- Development stage
- Preclinical
- Lead developer
- Kolab
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
KL271 is a **probiotic strain of Limosilactobacillus fermentum** being developed by Kolab for **aging-related oxidative stress**. The candidate is in **preclinical development** and appears intended for **oral administration**, supported by reported survival at **pH 2.0** consistent with gastric acid resistance. Preclinical data indicate antioxidant and anti-inflammatory activity, with reported effects on oxidative stress-related pathways and markers including **glutamate-cysteine ligase**, **glutathione peroxidase**, **catalase**, and **superoxide dismutase**; it has also been described as improving cognitive impairment and memory loss in experimental settings through antioxidant and anti-inflammatory mechanisms. KL271 is part of Kolab's proprietary probiotic pipeline rather than a conventional small-molecule pharmaceutical program.
- Other names
- Limosilactobacillus fermentum KL271
02
Targets
GPX1 (Glutathione peroxidase 1)Misfolded SOD1GCL (Gamma-glutamylcysteine Synthetase)Neuraminidase
Beyond the preview
Go deeper on KL271.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KL271.